Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy

H Bismuth, R Adam, F Lévi, C Farabos, F Waechter, D Castaing, P Majno, L Engerran, H Bismuth, R Adam, F Lévi, C Farabos, F Waechter, D Castaing, P Majno, L Engerran

Abstract

Objective: The authors discuss the technique and evaluate the results of an aggressive surgical approach in patients with primarily unresectable colorectal liver metastases that were downstaged by chronomodulated chemotherapy.

Background: Resection is the best treatment of colorectal liver metastases, but it may be achieved in only 10% of patients. In the remaining 90%, survival is poor, even after partial response to chemotherapy. Little is known about the results of curative hepatectomy in patients whose metastases are downstaged by chemotherapy.

Patients and methods: Fifty-three patients with colorectal liver metastases initially unresectable because of ill located (8), large (8), multinodular (24) lesions, or because of extrahepatic disease (13) were downstaged by a systemic chronomodulated chemotherapy associating 5-fluorouracil, folinic acid and Oxaliplatin to the point that operation could be performed. This consisted of a major hepatectomy in 37 patients and a minor resection in 16. Associated procedures (including 5 two-stage hepatectomies and 3 pulmonary resections) were performed in 25 patients.

Results: There was no operative mortality. Complications occurred in 14 patients. The cumulative 3- and 5-year survival rates were 54% and 40% (according to the type of lesions: ill-located, 75% and 48%; large, 62% and 62%; multinodular, 54% and 40%; extrahepatic, 43% and 14%). Hepatic recurrence (34 patients, 64%) was amenable to repeat surgery in 15 cases.

Conclusions: Liver resection may be achieved in some previously unresectable patients with the help of an effective chemotherapy. The benefit in survival seems comparable to that obtained with primary liver resection (40% at 5 years). This therapeutic strategy involves a multimodal approach, including repeat hepatectomies and extrahepatic surgery.

References

    1. N Engl J Med. 1994 Apr 21;330(16):1136-42
    1. BMJ. 1993 Mar 20;306(6880):752-5
    1. Lancet. 1994 Nov 5;344(8932):1255-60
    1. J Am Coll Surg. 1995 Feb;180(2):213-9
    1. World J Surg. 1995 Jan-Feb;19(1):59-71
    1. J Am Coll Surg. 1995 Sep;181(3):266-9
    1. N Engl J Med. 1978 Nov 9;299(19):1049-52
    1. Cancer. 1981 Jan 1;47(1):207-14
    1. Am J Surg. 1981 May;141(5):586-9
    1. World J Surg. 1982 Jan;6(1):3-9
    1. Ann Surg. 1984 Mar;199(3):306-16
    1. Arch Surg. 1984 Jun;119(6):647-51
    1. J Clin Oncol. 1987 Oct;5(10):1559-65
    1. Ann Surg. 1987 Dec;206(6):685-93
    1. Surgery. 1988 Mar;103(3):278-88
    1. J Clin Oncol. 1988 Mar;6(3):469-75
    1. Scand J Gastroenterol Suppl. 1988;149:144-9
    1. Ann Surg. 1989 Aug;210(2):127-38
    1. J Clin Oncol. 1989 Oct;7(10):1407-18
    1. Br J Surg. 1990 Jan;77(1):21-6
    1. J Natl Cancer Inst. 1990 Jun 20;82(12):1046-50
    1. Br J Surg. 1990 Nov;77(11):1241-6
    1. Cancer. 1992 Feb 15;69(4):893-900
    1. Gastroenterol Clin Biol. 1991;15(10):758-61
    1. J Surg Oncol. 1992 Oct;51(2):122-5
    1. Br J Surg. 1993 Mar;80(3):274-6
    1. Lancet. 1994 Jun 4;343(8910):1405-10

Source: PubMed

3
購読する